<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01230814</url>
  </required_header>
  <id_info>
    <org_study_id>09-0070</org_study_id>
    <secondary_id>DMID STI CTG 09-0070 PVI</secondary_id>
    <nct_id>NCT01230814</nct_id>
  </id_info>
  <brief_title>Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women</brief_title>
  <official_title>A Double-Blind, Randomized Trial of Monthly Treatment With Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories Versus Placebo for Preventing Vaginal Infections in HIV-seronegative Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      This research study is about vaginal infections such as bacterial vaginosis, yeast
      infections, and trichomoniasis. Usually, these infections can be treated with medication, but
      sometimes they come back after treatment. Researchers want to know if using vaginal
      suppositories can decrease the risk of vaginal infections. Participants will include 234
      women who are sexually active (greater than or equal to 4 episodes of sex with men during the
      past month), HIV-negative, 18 to 45 years old, with bacterial infection [vaginosis and/or
      vulvovaginal candidiasis (VVC) and/or Trichomonas vaginalis] detected by laboratory testing
      at a screening visit. Women will receive vaginal suppositories containing drug or inactive
      ingredients (placebo). Participation in the study will be about 12 months. Study procedures
      include: urine and blood tests, physical exams, and questionnaires.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vaginal infections including bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and
      Trichomonas (T.) vaginalis are common and have been associated with increased risk of HIV and
      other sexually transmitted infections (STIs) in multiple prospective studies. Effective
      interventions for prevention of vaginal infections could substantially reduce the risk of HIV
      and other STIs in women. A recently completed trial has demonstrated that monthly periodic
      presumptive treatment (PPT) can reduce vaginal infections and promote Lactobacillus
      colonization. However, the oral regimen of metronidazole 2 grams plus fluconazole 150 mg was
      not sufficiently effective to warrant moving to Phase III HIV/STI prevention trials using
      this intervention. The identification of more efficacious regimens for reducing vaginal
      infections is a crucial step towards the development of inexpensive, female-controlled,
      non-coitally dependent HIV/STI risk reduction interventions for women. There is growing
      evidence that higher doses and longer courses may be more effective for treatment of vaginal
      infections than single-dose therapy. The overall goal of this protocol is to conduct a
      randomized, double-blind, placebo-controlled trial to test the efficacy of monthly PPT with
      topical metronidazole 750 mg plus miconazole 200 mg (co-formulated suppositories) versus
      matching placebo suppositories nightly for five nights each month for reducing the rates of
      BV and VVC among HIV-seronegative women. This regimen could produce sufficient reductions in
      vaginal infections to support its use in Phase III HIV and STI prevention trials. The study
      participants will include 234 women who are sexually active (greater than or equal to 4
      episodes of heterosexual intercourse during the past month), HIV-seronegative, 18 to 45 years
      old, with BV and/or VVC and/or T. vaginalis detected by laboratory testing at a screening
      visit. There will be two study arms. The treatment arm (117 subjects) will receive PPT with
      intravaginal metronidazole 750 mg plus miconazole 200 mg (co-formulated suppositories) for
      five consecutive nights each month. The placebo arm (117 subjects) will receive PPT with
      identical placebo intravaginal suppositories for five consecutive nights each month.
      Individual participants will be in the study for one year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing Vulvovaginal Candidiasis (VVC).</measure>
    <time_frame>Months 2, 4, 6, 8, 10, and 12.</time_frame>
    <description>Percentage of follow-up visits (Months 2, 4, 6, 8, 10, 12) positive for VVC based on the presence of fungal elements (pseudohyphae, blastoconidia, or both) on vaginal saline wet mount plus a positive culture showing yeast on Sabouraud's agar.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing Bacterial Vaginosis (BV).</measure>
    <time_frame>Months 2, 4, 6, 8, 10, and 12.</time_frame>
    <description>Percentage of follow-up visits (Months 2, 4, 6, 8, 10, 12) positive for BV as determined by applying standard microscopic scoring criteria (Nugent's criteria) to vaginal Gram stained slides. BV is diagnosed when the score is greater than or equal to 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Placebo for Preventing Any Vaginal Infection (a Combined Endpoint Including BV, VVC, and Trichomonas Vaginalis Infection).</measure>
    <time_frame>Months 2, 4, 6, 8, 10, and 12.</time_frame>
    <description>Percentage of follow-up visits (Months 2, 4, 6, 8, 10, 12) positive for any of three vaginal infections (BV, VVC, Trichomonas vaginalis infection).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing BV by Clinical Criteria (Amsel's Criteria).</measure>
    <time_frame>Months 2, 4, 6, 8, 10, and 12.</time_frame>
    <description>Percentage of follow-up visits (Months 2, 4, 6, 8, 10, 12) positive for BV by clinical criteria (Amsel's criteria).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">234</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <condition>Candidiasis</condition>
  <condition>Trichomoniasis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravaginal metronidazole 750 mg plus miconazole 200 mg (co-formulated suppositories) nightly for 5 consecutive nights each month; 117 Subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo suppositories nightly for five consecutive nights each month; 117 Subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neo-Penotran® Forte (active ingredient Metronidazole &amp; Miconazole Nitrate)</intervention_name>
    <description>Neo-Penotran® Forte (active ingredient Metronidazole &amp; Miconazole Nitrate), co-formulated vaginal suppositories containing metronidazole 750 mg with miconazole 200 mg and excipients (Witepsol S 55). Witepsol S 55 is a hard fat suppository base. Such bases consist mainly of triglyceride esters of the higher saturated fatty acids along with varying proportions of mono- and diglycerides. 117 subjects receive nightly for 5 consecutive night each month.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo vaginal suppositories, identical in appearance to the active product; contains Witepsol S 55, Titanium Dioxide and D+C yellow #10 with no metronidazole or miconazole.117 subjects receive nightly for 5 consecutive nights each month.</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained and informed consent form (ICF) signed.

          -  Female, aged 18-45 years.

          -  Sexually active with greater than or equal to 4 episodes of sex with a male partner
             during the past month.

          -  Human immunodeficiency virus (HIV)-seronegative on both HIV tests in parallel
             screening.

          -  Presence of bacterial vaginosis (BV) and/or vulvovaginal candidiasis (VVC) and/or T.
             vaginalis infection at screening:

               1. BV: Microscopic criteria (Nugent's score greater than or equal to 7)

               2. VVC: Fungal elements (pseudohyphae, blastoconidia, or both) on vaginal saline wet
                  mount plus a positive culture showing yeast on Sabouraud's agar.

               3. T. vaginalis infection: Identification of motile trichomonads on vaginal saline
                  wet preparation.

          -  Able and willing to comply with study visit schedule and procedures during the
             12-month period of follow-up.

          -  Able and willing to abstain from sex or to use non-latex condoms (provided) for 24
             hours following insertion of each vaginal suppository.

          -  Willing to abstain from alcohol during, and for 48 hours after, treatment.

          -  Plan to remain in study area for the next year.

          -  Agree to not participate in other research studies involving drugs, medical devices,
             or vaginal products for the duration of study.

        Exclusion Criteria:

          -  Currently pregnant (positive urine Beta-Human Chorionic Gonadotropin (hCG) or planning
             to conceive during the next 12 months (by self-report).

          -  Currently breastfeeding.

          -  Within first 3 months post-partum.

          -  Current menstruation - women who are currently menstruating may be enrolled following
             the completion of menses.

          -  History of 4 or more episodes of treatment for any vaginal infection in the past 12
             months. This would be a cumulative total, including any treatment for bacterial
             vaginosis (BV) and/or vulvovaginal candidiasis (VVC) and/or Trichomonas vaginalis (TV)
             and/or syndromic.

          -  History of medical condition that would contraindicate use of the study product

               1. Porphyria

               2. Epilepsy

               3. Serious liver disease or signs and symptoms consistent with serious liver disease
                  including jaundice, ascites, esophageal varices, encephalopathy, and bleeding
                  disorders.

               4. Renal failure

          -  History of adverse reaction to the study medications (intravaginal metronidazole or
             miconazole).

          -  Current use of medication that may interact with the study drug (due to vaginal
             absorption of study drug)

               1. Warfarin

               2. Phenytoin

               3. Phenobarbital

               4. Disulfiram

               5. Cimetidine

               6. Lithium

               7. Astemizole

               8. Terfenadine

          -  Current use of oral or intravaginal antifungal medication.

          -  Current use of oral or intravaginal metronidazole, tinidazole, or clindamycin.

          -  Current use of latex diaphragm.

          -  As determined by the investigator, a medical condition or situation exists such that
             study participation would not be advisable.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Project - Ganjoni Municipal Clinic</name>
      <address>
        <city>Mombasa</city>
        <state>Coast</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nairobi - Center for STD/HIV Research &amp; Training</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nairobi - Kenya AIDS Vaccine Initiative</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2010</study_first_submitted>
  <study_first_submitted_qc>October 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2010</study_first_posted>
  <results_first_submitted>August 14, 2014</results_first_submitted>
  <results_first_submitted_qc>September 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2014</results_first_posted>
  <last_update_submitted>September 26, 2014</last_update_submitted>
  <last_update_submitted_qc>September 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bacterial vaginosis, metronidazole, miconazole, vulvovaginal candidiasis, trichomonas vaginalis, women, Kenya</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Trichomonas Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Metronidazole Plus Miconazole</title>
          <description>Intravaginal metronidazole 750 mg plus miconazole 200 mg (co-formulated suppositories) nightly for 5 consecutive nights each month.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Placebo</title>
          <description>Placebo suppositories nightly for five consecutive nights each month.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued (not due to adverse event)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: Metronidazole Plus Miconazole</title>
          <description>Intravaginal metronidazole 750 mg plus miconazole 200 mg (co-formulated suppositories) nightly for 5 consecutive nights each month.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Placebo</title>
          <description>Placebo suppositories nightly for five consecutive nights each month.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="118"/>
            <count group_id="B2" value="116"/>
            <count group_id="B3" value="234"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" lower_limit="24" upper_limit="34"/>
                    <measurement group_id="B2" value="29" lower_limit="23" upper_limit="35"/>
                    <measurement group_id="B3" value="29" lower_limit="24" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kenya</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing Vulvovaginal Candidiasis (VVC).</title>
        <description>Percentage of follow-up visits (Months 2, 4, 6, 8, 10, 12) positive for VVC based on the presence of fungal elements (pseudohyphae, blastoconidia, or both) on vaginal saline wet mount plus a positive culture showing yeast on Sabouraud’s agar.</description>
        <time_frame>Months 2, 4, 6, 8, 10, and 12.</time_frame>
        <population>Intention to treat population which consisted of all women who were randomized and had at least one follow-up visit. Two women in the metronidazole with miconazole arm did not return after enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Metronidazole Plus Miconazole</title>
            <description>Intravaginal metronidazole 750 mg plus miconazole 200 mg (co-formulated suppositories) nightly for 5 consecutive nights each month.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Placebo</title>
            <description>Placebo suppositories nightly for five consecutive nights each month.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing Vulvovaginal Candidiasis (VVC).</title>
          <description>Percentage of follow-up visits (Months 2, 4, 6, 8, 10, 12) positive for VVC based on the presence of fungal elements (pseudohyphae, blastoconidia, or both) on vaginal saline wet mount plus a positive culture showing yeast on Sabouraud’s agar.</description>
          <population>Intention to treat population which consisted of all women who were randomized and had at least one follow-up visit. Two women in the metronidazole with miconazole arm did not return after enrollment.</population>
          <units>percentage of follow-up visits</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Follow-up visits</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="645"/>
                <count group_id="O2" value="665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="8.2" upper_limit="13.2"/>
                    <measurement group_id="O2" value="11.3" lower_limit="9.0" upper_limit="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Each participant within a study arm was considered a cluster, with observations at a maximum of 6 visits. The percentage of visits at which VVC was detected was compared between metronidazole plus miconazole arm versus placebo arm using a chi-squared statistic adjusted for clustering using the method of Donner and Klar (2000).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.690</p_value>
            <p_value_desc>The a priori threshold for statistical significance for VVC was p&lt;0.020 (two-sided).</p_value_desc>
            <method>Clustered chi-squared statistic</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
            <estimate_desc>For the relative risk estimate, the metronidazole plus miconazole arm represented the numerator and the placebo arm represented the denominator such that a relative risk &lt;1 indicates a lower percentage of positive test visits in the treated arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing Bacterial Vaginosis (BV).</title>
        <description>Percentage of follow-up visits (Months 2, 4, 6, 8, 10, 12) positive for BV as determined by applying standard microscopic scoring criteria (Nugent’s criteria) to vaginal Gram stained slides. BV is diagnosed when the score is greater than or equal to 7.</description>
        <time_frame>Months 2, 4, 6, 8, 10, and 12.</time_frame>
        <population>Intention to treat population which consisted of all women who were randomized and had at least one follow-up visit. Two women in the metronidazole with miconazole arm did not return after enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Metronidazole Plus Miconazole</title>
            <description>Intravaginal metronidazole 750 mg plus miconazole 200 mg (co-formulated suppositories) nightly for 5 consecutive nights each month.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Placebo</title>
            <description>Placebo suppositories nightly for five consecutive nights each month.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing Bacterial Vaginosis (BV).</title>
          <description>Percentage of follow-up visits (Months 2, 4, 6, 8, 10, 12) positive for BV as determined by applying standard microscopic scoring criteria (Nugent’s criteria) to vaginal Gram stained slides. BV is diagnosed when the score is greater than or equal to 7.</description>
          <population>Intention to treat population which consisted of all women who were randomized and had at least one follow-up visit. Two women in the metronidazole with miconazole arm did not return after enrollment.</population>
          <units>percentage of follow-up visits</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Follow-up Visits</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="645"/>
                <count group_id="O2" value="665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" lower_limit="18.0" upper_limit="25.1"/>
                    <measurement group_id="O2" value="32.5" lower_limit="28.4" upper_limit="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Each participant within a study arm was considered a cluster, with observations at a maximum of 6 visits. The percentage of visits at which BV was detected was compared between metronidazole plus miconazole arm versus placebo arm using a chi-squared statistic adjusted for clustering using the method of Donner and Klar (2000).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>The a priori threshold for statistical significance for BV was p&lt;0.030 (two-sided).</p_value_desc>
            <method>clutstered chi-squared statistic</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
            <estimate_desc>For the relative risk estimate, the metronidazole plus miconazole arm represented the numerator and the placebo arm represented the denominator such that a relative risk &lt;1 indicates a lower percentage of test visits in the treated arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Placebo for Preventing Any Vaginal Infection (a Combined Endpoint Including BV, VVC, and Trichomonas Vaginalis Infection).</title>
        <description>Percentage of follow-up visits (Months 2, 4, 6, 8, 10, 12) positive for any of three vaginal infections (BV, VVC, Trichomonas vaginalis infection).</description>
        <time_frame>Months 2, 4, 6, 8, 10, and 12.</time_frame>
        <population>Intention to treat population which consisted of all women who were randomized and had at least one follow-up visit. Two women in the metronidazole with miconazole arm did not return after enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Metronidazole Plus Miconazole</title>
            <description>Intravaginal metronidazole 750 mg plus miconazole 200 mg (co-formulated suppositories) nightly for 5 consecutive nights each month.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Placebo</title>
            <description>Placebo suppositories nightly for five consecutive nights each month.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Placebo for Preventing Any Vaginal Infection (a Combined Endpoint Including BV, VVC, and Trichomonas Vaginalis Infection).</title>
          <description>Percentage of follow-up visits (Months 2, 4, 6, 8, 10, 12) positive for any of three vaginal infections (BV, VVC, Trichomonas vaginalis infection).</description>
          <population>Intention to treat population which consisted of all women who were randomized and had at least one follow-up visit. Two women in the metronidazole with miconazole arm did not return after enrollment.</population>
          <units>percentage of follow-up visits</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Follow-up visits</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="645"/>
                <count group_id="O2" value="665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" lower_limit="28.4" upper_limit="37.3"/>
                    <measurement group_id="O2" value="46.5" lower_limit="41.6" upper_limit="51.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing BV by Clinical Criteria (Amsel’s Criteria).</title>
        <description>Percentage of follow-up visits (Months 2, 4, 6, 8, 10, 12) positive for BV by clinical criteria (Amsel's criteria).</description>
        <time_frame>Months 2, 4, 6, 8, 10, and 12.</time_frame>
        <population>Intention to treat population which consisted of all women who were randomized and had at least one follow-up visit. Two women in the metronidazole with miconazole arm did not return after enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Metronidazole Plus Miconazole</title>
            <description>Intravaginal metronidazole 750 mg plus miconazole 200 mg (co-formulated suppositories) nightly for 5 consecutive nights each month.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Placebo</title>
            <description>Placebo suppositories nightly for five consecutive nights each month.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing BV by Clinical Criteria (Amsel’s Criteria).</title>
          <description>Percentage of follow-up visits (Months 2, 4, 6, 8, 10, 12) positive for BV by clinical criteria (Amsel's criteria).</description>
          <population>Intention to treat population which consisted of all women who were randomized and had at least one follow-up visit. Two women in the metronidazole with miconazole arm did not return after enrollment.</population>
          <units>percentage of follow-up visits</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Follow-up visits</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="645"/>
                <count group_id="O2" value="665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" lower_limit="11.8" upper_limit="17.7"/>
                    <measurement group_id="O2" value="18.2" lower_limit="15.2" upper_limit="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Months 2, 4, 6, 8, 10, and 12, and any interim visits.</time_frame>
      <desc>Adverse events were followed until resolution even beyond the study-reporting period. Resolution of an adverse event is defined as the return to pretreatment status or stabilization of the condition with the expectation that it will remain chronic.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: Metronidazole Plus Miconazole</title>
          <description>Intravaginal metronidazole 750 mg plus miconazole 200 mg (co-formulated suppositories) nightly for 5 consecutive nights each month.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: Placebo</title>
          <description>Placebo suppositories nightly for five consecutive nights each month.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ruptured ectopic pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="116"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="116"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="116"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="116"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="116"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="116"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="116"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="116"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="116"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="116"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="116"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="116"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="31" subjects_affected="24" subjects_at_risk="116"/>
                <counts group_id="E2" events="53" subjects_affected="36" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="116"/>
                <counts group_id="E2" events="19" subjects_affected="12" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="24" subjects_affected="14" subjects_at_risk="116"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="116"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="55" subjects_affected="27" subjects_at_risk="116"/>
                <counts group_id="E2" events="67" subjects_affected="43" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Vaginal odour</sub_title>
                <counts group_id="E1" events="19" subjects_affected="10" subjects_at_risk="116"/>
                <counts group_id="E2" events="11" subjects_affected="5" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Vulvovaginal discomfort</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="116"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" events="62" subjects_affected="38" subjects_at_risk="116"/>
                <counts group_id="E2" events="78" subjects_affected="44" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="116"/>
                <counts group_id="E2" events="27" subjects_affected="19" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="116"/>
                <counts group_id="E2" events="24" subjects_affected="18" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="116"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="116"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="64" subjects_affected="40" subjects_at_risk="116"/>
                <counts group_id="E2" events="54" subjects_affected="36" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="116"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shelly Lensing, MS</name_or_title>
      <organization>University of Arkansas for Medical Sciences</organization>
      <phone>501-686-8203</phone>
      <email>sylensing@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

